Q-omics provides the consensus-scored NGLY1 profile across patient tissues and cancer cell-line models. NGLY1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, NGLY1 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, NGLY1 RNA expression shows 20,184 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight READ, LIHC, and ACC as cancer lineages where NGLY1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NGLY1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NGLY1 survival associations across molecular data types. NGLY1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NGLY1 RNA expression–survival associations across cancer types. High NGLY1 expression shows unfavorable associations in LIHC, KICH and LGG, but favorable associations in READ, KIRC and COAD. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for NGLY1 RNA expression.
This table summarizes NGLY1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NGLY1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NGLY1 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, BLCA, STAD and CHOL. The LIHC box plot shows higher NGLY1 RNA expression in tumor versus normal tissue (log2 FC = +0.636, t-test p < 0.001).
This table shows molecular features associated with NGLY1 in patient tissues and cancer cell lines. In patient samples, NGLY1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NGLY1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
